

December 27, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release - Tergene Biotech Pvt. Ltd., a Joint Venture company, receives SEC recommendation for pneumococcal 15 valent (PCV15) vaccine.

We enclose a copy of the Press Release that is being issued by the Company in connection with recommendation of granting permission to the JV company, Tergene Biotech Pvt. Ltd., to manufacture and market 15-valent Pneumococcal Polysaccharide Conjugate Vaccine.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: as above.

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 402374 1080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com

Hyderabad, India, December 27, 2022

Tergene Biotech Pvt. Ltd., a Joint Venture company, receives SEC recommendation for pneumococcal 15 valent (PCV15) vaccine.

Aurobindo Pharma Ltd is pleased to announce that Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO), in its minutes for the meeting held on 21st Dec 2022, has recommended grant of permission to its JV company Tergene to manufacture and market 15-valent Pneumococcal Polysaccharide Conjugate Vaccine with three dose schedule (3 +0) for administration into the pediatric age group of 6, 10 and 14 weeks. PCV15 vaccine was developed by Tergene Biotech Pvt. Ltd. and manufactured at AuroVaccines Pvt. Ltd., which is a wholly owned subsidiary of Aurobindo Pharma Ltd with capabilities in vaccines development and manufacturing. Aurobindo Pharma Ltd holds 80% stake in the Joint Venture company, Tergene Biotech Pvt. Ltd.

Commenting on the development, Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director said, “SEC’s recommendation is based on data from (3+0) trial conducted in 1130 pediatric subjects assessing safety, tolerability, and immunogenicity. By assessing opsonophagocytic activity (OPA) and Geometric Mean IgG Titers (GMTs), we have demonstrated through our clinical data that our test product is non-inferior to the currently available 13-valent pneumococcal conjugate vaccine for the thirteen shared serotypes and provided good immune response for the two additional serotypes unique to our vaccine (serotypes 2 and 12F).”

With SEC’s recommendation, we will take the procedural next steps as we expect formal approval from DCGI in the coming weeks. At Aurobindo, through our 15 valent conjugate vaccine (serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F and 23F), we are committed to protecting infants from pneumococcal disease by eliciting a strong immune response in them to each serotype covered in the vaccine. Further, we will continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come.”

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 24 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

For further information or queries, please contact:

Soumen Biswas | Deepti Thakur
Investor Relations | Corporate Communications
Phone: +91 40 66725401 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,
Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833